Literature DB >> 30471200

MALDI-Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods.

Oliver Klein1,2, Frederic Kanter3, Hagen Kulbe1,4,5, Paul Jank1,6, Carsten Denkert1,6, Grit Nebrich1,2, Wolfgang D Schmitt1,6, Zhiyang Wu1,2, Catarina A Kunze1,6, Jalid Sehouli1,4,5, Silvia Darb-Esfahani1,7, Ioana Braicu1,4,5, Jan Lellmann3, Herbert Thiele5, Eliane T Taube1,6.   

Abstract

PURPOSE: Precise histological classification of epithelial ovarian cancer (EOC) has immanent diagnostic and therapeutic consequences, but remains challenging in histological routine. The aim of this pilot study is to examine the potential of matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry in combination with machine learning methods to classify EOC histological subtypes from tissue microarray. EXPERIMENTAL
DESIGN: Formalin-fixed-paraffin-embedded tissue of 20 patients with ovarian clear-cell, 14 low-grade serous, 19 high-grade serous ovarian carcinomas, and 14 serous borderline tumors are analyzed using MALDI-Imaging. Classifications are computed by linear discriminant analysis (LDA), support vector machines with linear (SVM-lin) and radial basis function kernels (SVM-rbf), a neural network (NN), and a convolutional neural network (CNN).
RESULTS: MALDI-Imaging and machine learning methods result in classification of EOC histotypes with mean accuracy of 80% for LDA, 80% SVM-lin, 74% SVM-rbf, 83% NN, and 85% CNN. Based on sensitivity (69-100%) and specificity (90-99%), CCN and NN are most suited to EOC classification. CONCLUSION AND CLINICAL RELEVANCE: The pilot study demonstrates the potential of MALDI-Imaging derived proteomic classifiers in combination with machine learning algorithms to discriminate EOC histotypes. Applications may support the development of new prognostic parameters in the assessment of EOC.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  histotype classification; imaging mass spectrometry; machine learning; ovarian cancer

Mesh:

Year:  2018        PMID: 30471200     DOI: 10.1002/prca.201700181

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  11 in total

Review 1.  Mass spectrometry imaging to detect lipid biomarkers and disease signatures in cancer.

Authors:  Matthias Holzlechner; Eliseo Eugenin; Brendan Prideaux
Journal:  Cancer Rep (Hoboken)       Date:  2019-12

2.  Immune-and Metabolism-Associated Molecular Classification of Ovarian Cancer.

Authors:  Zhenyue Chen; Weiyi Jiang; Zhen Li; Yun Zong; Gaopi Deng
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

Review 3.  Novel methods in adrenal research: a metabolomics approach.

Authors:  Thomas G Papathomas; Na Sun; Vasileios Chortis; Angela E Taylor; Wiebke Arlt; Susan Richter; Graeme Eisenhofer; Gerard Ruiz-Babot; Leonardo Guasti; Axel Karl Walch
Journal:  Histochem Cell Biol       Date:  2019-02-06       Impact factor: 4.304

4.  INFORM: INFrared-based ORganizational Measurements of tumor and its microenvironment to predict patient survival.

Authors:  Saumya Tiwari; Andre Kajdacsy-Balla; Joshua Whiteley; Georgina Cheng; Stephen M Hewitt; Rohit Bhargava
Journal:  Sci Adv       Date:  2021-02-03       Impact factor: 14.136

5.  Peptide Signatures for Prognostic Markers of Pancreatic Cancer by MALDI Mass Spectrometry Imaging.

Authors:  Florian N Loch; Oliver Klein; Katharina Beyer; Frederick Klauschen; Christian Schineis; Johannes C Lauscher; Georgios A Margonis; Claudius E Degro; Wael Rayya; Carsten Kamphues
Journal:  Biology (Basel)       Date:  2021-10-12

6.  In Situ N-Glycosylation Signatures of Epithelial Ovarian Cancer Tissue as Defined by MALDI Mass Spectrometry Imaging.

Authors:  Marta Grzeski; Eliane T Taube; Elena I Braicu; Jalid Sehouli; Véronique Blanchard; Oliver Klein
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639

7.  Diagnosis of melanoma by imaging mass spectrometry: Development and validation of a melanoma prediction model.

Authors:  Rami N Al-Rohil; Jessica L Moore; Nathan Heath Patterson; Sarah Nicholson; Nico Verbeeck; Marc Claesen; Jameelah Z Muhammad; Richard M Caprioli; Jeremy L Norris; Sara Kantrow; Margaret Compton; Jason Robbins; Ahmed K Alomari
Journal:  J Cutan Pathol       Date:  2021-07-02       Impact factor: 1.587

8.  MALDI-MSI-A Step Forward in Overcoming the Diagnostic Challenges in Ovarian Tumors.

Authors:  Dagmara Pietkiewicz; Agnieszka Horała; Szymon Plewa; Piotr Jasiński; Ewa Nowak-Markwitz; Zenon J Kokot; Jan Matysiak
Journal:  Int J Environ Res Public Health       Date:  2020-10-18       Impact factor: 3.390

9.  Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging.

Authors:  Wanja Kassuhn; Oliver Klein; Silvia Darb-Esfahani; Hedwig Lammert; Sylwia Handzik; Eliane T Taube; Wolfgang D Schmitt; Carlotta Keunecke; David Horst; Felix Dreher; Joshy George; David D Bowtell; Oliver Dorigo; Michael Hummel; Jalid Sehouli; Nils Blüthgen; Hagen Kulbe; Elena I Braicu
Journal:  Cancers (Basel)       Date:  2021-03-25       Impact factor: 6.639

10.  MicroRNA expression integrated analysis and identification of novel biomarkers in small cell lung cancer: a meta-analysis.

Authors:  Dandan Han; Lailing Li; Xin Ge; Dan Li; Xiaolei Zhang
Journal:  Transl Cancer Res       Date:  2020-05       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.